{"publication_id":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","content_hash":"sha256:a1e2bda554e0820a678f2b06de3d0cfb83ce644eede52e3dc9ec99056768ff88","nodes":[{"id":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","type":"publication","title":"fisetin: one bounded, context-dependent signal across receipts"},{"id":"claim_1","type":"claim","text":"Across retrieved fact-level receipts for fisetin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?"},{"id":"claim_2","type":"claim","text":"Finding: DHC and fisetin caused dose-dependent reduction in viability and increase in apoptosis in PC3 cells at 72 h."},{"id":"claim_3","type":"claim","text":"This receipt-backed scoping note has one bounded signal: fisetin shows endpoint-specific favorable signals with context limits across this 5-source primary bundle (2010-2023). Grouped by direction: directionally favorable: 3 receipt(s) | other/mixed: 2 receipt(s). The source facts cover 5 population context(s) and 4 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete source-level examples: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells; DHC and fisetin caused dose-dependent reduction in viability and increase in apoptosis in PC3 cells at 72 h; Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001);."},{"id":"claim_4","type":"claim","text":"null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable."},{"id":"claim_5","type":"claim","text":"directionally favorable: Antiproliferative Mechanisms of the Flavonoids 2,2′-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells — DHC and fisetin caused dose-dependent reduction in viability and increase in apoptosis in PC3 cells at 72 h."},{"id":"claim_6","type":"claim","text":"directionally favorable: &lt;p&gt;Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies&lt;/p&gt; — Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001); ( mechanistic ablation supports the topic effect; not a comparator outcome)"},{"id":"claim_7","type":"claim","text":"directionally favorable: Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models — Fisetin treatment significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2. ( mechanistic ablation supports the topic effect; not a comparator outcome)"},{"id":"claim_8","type":"claim","text":"Specific moderators in this bundle are population/indication (HEKa cells (adult human epidermal keratinocytes); Human U937-DC-SIGN macrophages infected with dengue virus serotypes 2 or 3; PC3 human prostate cancer cells; TNF-α stimulated NHEKs; senescent human umbilical vein endothelial cells (HUVECs)), study design/evidence type (primary)."},{"id":"claim_9","type":"claim","text":"The selected receipts group because each carries a fact-level extraction for fisetin; they separate by context (human clinical/observational and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim."},{"id":"claim_10","type":"claim","text":"The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate."},{"id":"source_1","type":"source","study":"Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence","year":2023,"doi":"10.1111/acel.14060","url":"https://doi.org/10.1111/acel.14060","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Antiproliferative Mechanisms of the Flavonoids 2,2′-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells","year":2010,"doi":"10.1080/01635581003605524","url":"https://doi.org/10.1080/01635581003605524","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"&lt;p&gt;Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies&lt;/p&gt;","year":2019,"doi":"10.2147/idr.s210890","url":"https://doi.org/10.2147/idr.s210890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation","year":2023,"doi":"10.3389/fimmu.2022.1075804","url":"https://doi.org/10.3389/fimmu.2022.1075804","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models","year":2019,"doi":"10.3390/cells8091089","url":"https://doi.org/10.3390/cells8091089","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_1","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_2","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_3","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_4","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_5","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_6","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_7","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_8","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_9","type":"contains_claim"},{"from":"f7aceb24-5650-43e9-8e4f-c8d8c3a376dd","to":"claim_10","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}